跳至主要内容
临床试验/EUCTR2004-001914-15-IT
EUCTR2004-001914-15-IT进行中(未招募)不适用

A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment of Antiretroviral-Naive HIV-1 Infected Subjects

Pfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 5820 个研究点目标入组 1,071 人开始时间: 2007年4月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1,071

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
Pfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582

相似试验

进行中(未招募)
不适用
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.Candidiasis (invasive)
EUCTR2005-004504-36-LVMerck & Co. Inc220
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose StudyCandidiasis (invasive)MedDRA version: 8.0 Level: LLT Classification code 10007152
EUCTR2005-004504-36-PTMerck sharp & Dohme, Lda.220
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose StudyCandidiasis (invasive)MedDRA version: 8.0 Level: LLT Classification code 10007152
EUCTR2005-004504-36-BEMerck Sharp & Dohme BV220
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose Study
EUCTR2005-004504-36-DEMerck & Co. Inc.220
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults. - MK-0991 High Dose Study
EUCTR2005-004504-36-CZMerck & Co., Inc.220
A Multicenter, Randomized, Double-Blind, Comparative... | 临床试验